Physics, makers of diagnostic radiopharmaceuticals and molecular imaging agents. | GE HealthCare plans to take full control ...
Merus' head and neck cancer candidate bolsters 'best-in-disease' profile with new data drop: analyst
With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...
Novocure has cleared a phase 3 clinical study in pancreatic cancer, showing its tumor-treating electric fields could help ...
Cancer-focused Alligator Bioscience is clamping down on costs, laying off 70% of its team in efforts to save around $6 ...
Each year, we assemble our list of marquee names in the Fierce 15—featuring the most innovative private companies and ...
GE HealthCare has unveiled a new mammography system with artificial intelligence-powered features that it says are aimed at ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
The FDA has rejected Applied Therapeutics’ attempt to win approval on the strength of a failed phase 3 trial, triggering a 75% drop in the biotech’s share price. Applied said the complete response ...
Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...
Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, ...
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback